PE20061075A1 - Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior - Google Patents
Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anteriorInfo
- Publication number
- PE20061075A1 PE20061075A1 PE2005001499A PE2005001499A PE20061075A1 PE 20061075 A1 PE20061075 A1 PE 20061075A1 PE 2005001499 A PE2005001499 A PE 2005001499A PE 2005001499 A PE2005001499 A PE 2005001499A PE 20061075 A1 PE20061075 A1 PE 20061075A1
- Authority
- PE
- Peru
- Prior art keywords
- patients
- autoimmune diseases
- combination
- vegf antibodies
- previous therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
REFERIDA A UN ANTICUERPO ANTAGONISTA DE LA ANGIOGENESIS, EL CUAL ES UN ANTICUERPO ANTI-VEGF TAL COMO BEVACIZUMAB. DICHO ANTAGONISTA DE ANGIOGENESIS PUEDE ADMINISTRARSE EN COMBINACION CON O EN SERIE DE UN AGENTE DMARD TAL COMO EL MTX O EN COMBINACION CON O EN SERIE CON UN INHIBIDOR DE TNF ALFA TAL COMO ETANERCEPT, INFLIXIMAB O ADALIMUMAB O EN COMBINACION O EN SERIE DE UN ANTAGONISTA QUE SE ENLAZA CON UN MARCADOR SUPERFICIAL DE LA CELULA B TAL COMO CD10, CD20, CD19, ENTRE OTROS. PARTICULARMENTE, EL ANTAGONISTA DE ANGIOGENESIS QUE COMPRENDE UN ANTICUERPO CONTRA CD20 PUEDE SER RITUXIMAB O 2H7 V16 HUMANIZADO. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES EN PACIENTES EN QUIENES HA FALLADO UN TRATAMIENTO ANTERIOR CON DMARDS O INHIBIDORES TNF ALFA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63716904P | 2004-12-17 | 2004-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061075A1 true PE20061075A1 (es) | 2006-11-15 |
Family
ID=36177836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001499A PE20061075A1 (es) | 2004-12-17 | 2005-12-16 | Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060134111A1 (es) |
EP (1) | EP1824885A1 (es) |
JP (1) | JP2008524241A (es) |
KR (1) | KR20070086218A (es) |
CN (1) | CN101120020A (es) |
AR (1) | AR052056A1 (es) |
AU (1) | AU2005316403A1 (es) |
BR (1) | BRPI0518105A (es) |
CA (1) | CA2587932A1 (es) |
CR (1) | CR9181A (es) |
IL (1) | IL183347A0 (es) |
MA (1) | MA29366B1 (es) |
MX (1) | MX2007007165A (es) |
NO (1) | NO20073651L (es) |
NZ (1) | NZ555286A (es) |
PE (1) | PE20061075A1 (es) |
RU (1) | RU2007126970A (es) |
SG (1) | SG158089A1 (es) |
SV (1) | SV2006002342A (es) |
TN (1) | TNSN07191A1 (es) |
TW (1) | TW200634026A (es) |
WO (1) | WO2006066086A1 (es) |
ZA (1) | ZA200704898B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1176981B1 (en) * | 1999-05-07 | 2005-11-30 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
EP1692182B1 (en) * | 2003-11-05 | 2010-04-07 | Roche Glycart AG | Cd20 antibodies with increased fc receptor binding affinity and effector function |
DK2229956T3 (da) | 2004-09-13 | 2013-07-29 | Genzyme Corp | Multimere konstruktioner |
GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010054221A2 (en) * | 2008-11-06 | 2010-05-14 | The Johns Hopkins University | Treatment of chronic inflammatory respiratory disorders |
SG196798A1 (en) * | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JP5680547B2 (ja) * | 2008-12-23 | 2015-03-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗血管形成活性を有するインヒビターのためのバイオマーカー |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
US9441029B2 (en) | 2010-08-06 | 2016-09-13 | Genzyme Corporation | VEGF antagonist compositions and uses thereof |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
BR112016022345A2 (pt) * | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
ES2622983T3 (es) * | 2015-02-11 | 2017-07-10 | Deutsches Krebsforschungszentrum | Terapia contra el cáncer con un parvovirus combinado con bevacizumab |
SG11202007927WA (en) | 2018-03-09 | 2020-09-29 | Agenus Inc | Anti-cd73 antibodies and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) * | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
CN101073668A (zh) * | 1999-04-28 | 2007-11-21 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2005
- 2005-12-16 KR KR1020077013483A patent/KR20070086218A/ko not_active Application Discontinuation
- 2005-12-16 CN CNA2005800481049A patent/CN101120020A/zh active Pending
- 2005-12-16 US US11/303,811 patent/US20060134111A1/en not_active Abandoned
- 2005-12-16 MX MX2007007165A patent/MX2007007165A/es not_active Application Discontinuation
- 2005-12-16 BR BRPI0518105-4A patent/BRPI0518105A/pt not_active IP Right Cessation
- 2005-12-16 WO PCT/US2005/045600 patent/WO2006066086A1/en active Application Filing
- 2005-12-16 PE PE2005001499A patent/PE20061075A1/es not_active Application Discontinuation
- 2005-12-16 JP JP2007546933A patent/JP2008524241A/ja not_active Withdrawn
- 2005-12-16 AR ARP050105315A patent/AR052056A1/es not_active Application Discontinuation
- 2005-12-16 SG SG200907898-1A patent/SG158089A1/en unknown
- 2005-12-16 RU RU2007126970/15A patent/RU2007126970A/ru not_active Application Discontinuation
- 2005-12-16 NZ NZ555286A patent/NZ555286A/en not_active IP Right Cessation
- 2005-12-16 SV SV2005002342A patent/SV2006002342A/es unknown
- 2005-12-16 TW TW094144950A patent/TW200634026A/zh unknown
- 2005-12-16 CA CA002587932A patent/CA2587932A1/en not_active Abandoned
- 2005-12-16 ZA ZA200704898A patent/ZA200704898B/xx unknown
- 2005-12-16 AU AU2005316403A patent/AU2005316403A1/en not_active Abandoned
- 2005-12-16 EP EP05854343A patent/EP1824885A1/en not_active Withdrawn
-
2007
- 2007-05-18 TN TNP2007000191A patent/TNSN07191A1/fr unknown
- 2007-05-21 IL IL183347A patent/IL183347A0/en unknown
- 2007-06-13 CR CR9181A patent/CR9181A/es not_active Application Discontinuation
- 2007-07-12 MA MA30069A patent/MA29366B1/fr unknown
- 2007-07-16 NO NO20073651A patent/NO20073651L/no not_active Application Discontinuation
-
2008
- 2008-02-19 US US12/033,557 patent/US20080214789A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200634026A (en) | 2006-10-01 |
EP1824885A1 (en) | 2007-08-29 |
ZA200704898B (en) | 2009-03-25 |
BRPI0518105A (pt) | 2008-11-04 |
NZ555286A (en) | 2010-04-30 |
MX2007007165A (es) | 2007-08-14 |
CR9181A (es) | 2008-07-31 |
CN101120020A (zh) | 2008-02-06 |
MA29366B1 (fr) | 2008-04-01 |
AR052056A1 (es) | 2007-02-28 |
CA2587932A1 (en) | 2006-06-22 |
WO2006066086A1 (en) | 2006-06-22 |
TNSN07191A1 (en) | 2008-11-21 |
AU2005316403A1 (en) | 2006-06-22 |
IL183347A0 (en) | 2007-09-20 |
NO20073651L (no) | 2007-09-10 |
US20060134111A1 (en) | 2006-06-22 |
US20080214789A1 (en) | 2008-09-04 |
JP2008524241A (ja) | 2008-07-10 |
SG158089A1 (en) | 2010-01-29 |
RU2007126970A (ru) | 2009-01-27 |
KR20070086218A (ko) | 2007-08-27 |
SV2006002342A (es) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20061075A1 (es) | Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior | |
CY1111703T1 (el) | Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους | |
JP2017507953A5 (es) | ||
ES2909720T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina | |
PE20160999A1 (es) | Metodos para administrar anticuerpos anti-tnf-alfa | |
AU2016266708B2 (en) | Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
AR045710A1 (es) | Uso de inhibidores de tnf alfa y composiciones farmaceuticas que los comprenden para el tratamiento a dosis bajas | |
PE20201146A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
MX2010005099A (es) | Usos de anticuerpos anti-cd40. | |
WO2007053661A3 (en) | Uses of anti-cd40 antibodies | |
KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
AU2022202800B2 (en) | Combinations and uses thereof | |
JP2014525925A5 (es) | ||
AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
CA3037246A1 (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
AR077848A1 (es) | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado | |
AR110470A1 (es) | Terapia de combinación para tratar la enfermedad de alzheimer | |
RU2008140661A (ru) | Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа | |
AR115106A1 (es) | Método de tratamiento de cánceres y de potenciación de la eficacia de terapéuticas de redireccionamiento de células t | |
NZ749159A (en) | Anti-canine platelet derived growth factor receptor alpha antibody | |
Delfino et al. | Brentuximab vedotin in CD30-expressing cutaneous T-cell lymphoma | |
NZ617771B2 (en) | Combination therapy with an anti - cd19 antibody and a purine analog |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |